Close Menu

NEW YORK (GenomeWeb) – Adaptive Biotechnologies aims to raise up to $230 million in an initial public offering, according to documents filed yesterday with the US Securities and Exchange Commission.

The Seattle, Washington-based immunosequencing firm did not disclose an expected share price range but said it plans to trade under the symbol ADPT on the Nasdaq. Goldman Sachs, JP Morgan, Bank of America, Merrill Lynch, Cowen, William Blair, Guggenheim Securities, and BTIG will serve as underwriters of the IPO.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
25

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.